Healthcare

Genetic Technologies Limited (ASX:GTG)

Industry Group : Pharmaceuticals, Biotechnology & Life Sciences | Industry Group Name : Life Sciences Tools & Services

Market Price : AUD 0.00750 (0%)

(as on 2021-10-24 00:10:38)

Market Cap : AUD 69.196 M

Previous Close Open Close* Day Range 52 WEEK HIGH LOW
0.0075 0.007 0.0075 0.007L 0.0075 H 0.006L 0.014 H
Last Trade 0.0075
Change% 0.0000
52 W H/L 0.014/0.006
EBITDA -7.064 M
NPAT After Abnormal Items -7.078 M
Equity 21.533 M
ROE% -32.87%
Total Liabilities 1.439 M
Total Revenue 1.623 M
Cash and Cash Equivalents 20.902 M

Stock Information

Share price 0.0075
Market Cap 69.196 M
Price/Gross Cash Flow -16.23
Dividend Yield Excluding Special 0.00%
Ending Shares 9.017 B
52-Week Range 0.006-0.014
P/E ratio 0.000
Sector P/E --
EPS -0.08
EV/EBITDA --
Net Profit Margin (%) -5,870.91%
Gross Cash Flows Per Share -0.00
Net Gearing -96.12%
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 0.000
Net Tangible Asset (NTA) 0.00
Sales Per Share 0.00
Book Value Per Share 0.00

Announcements

Heading Date/Time
Notice of Annual General Meeting/Proxy Form  22/10/2021 9:55AM
GTG delivers material increase in cash receipts  04/10/2021 9:58AM
Presentation to H.C. Wainwright Investment Conference  13/09/2021 8:21AM
Appendix 4G and Corporate Governance Statement  31/08/2021 9:49AM
Genetic Technologies FY21 Full Year Results  31/08/2021 9:40AM
Annual Report to Shareholders and Appendix 4E  31/08/2021 9:36AM
Change in substantial holding  17/08/2021 8:16AM
Completion of EasyDNA Acquisition set for global expansion  16/08/2021 9:42AM
Proposed issue of securities - GTG  13/08/2021 11:19AM
Cleansing Prospectus  13/08/2021 9:06AM
Notification of cessation of securities - GTG  12/08/2021 12:26PM
Company Secretary Appointment  03/08/2021 9:49AM
Genetic Technologies Investor Presentation and Webinar  28/07/2021 8:25AM
Quarterly Activities Report & Appendix 4C  26/07/2021 10:40AM
Updated Appendix 2A  21/07/2021 4:49PM
Change in substantial holding  21/07/2021 8:22AM
Application for quotation of securities - GTG  20/07/2021 9:52AM
Proposed issue of securities - GTG  19/07/2021 4:54PM
Genetic Technologies Acquires EasyDNA  19/07/2021 11:47AM
Response to ASX Query  28/06/2021 5:37PM
US Patent Office Grants Foundational Pharmacogenomic Patent  11/06/2021 3:37PM
GTG COVID-19 Risk Test launched in USA  01/06/2021 9:15AM
Trading Halt  28/05/2021 12:00PM
Change in substantial holding  26/05/2021 8:21AM
Quarterly Activities Report & Appendix 4C  29/04/2021 12:37PM
COVID- 19 Risk Test Approved for Commercial Release  26/04/2021 5:16PM
Genetic Technologies appoints Mike Tonroe as CFO  12/04/2021 10:44AM
GTG COVID-19 Risk Test launch update  09/04/2021 10:32AM
Appendix 3G  01/04/2021 5:31PM

Similar Companies

Related Articles

Load More

About Company

Diversified molecular diagnostics company Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE) is engaged in developing risk assessment tests based on genetic technology. The Company provides tests to predict an individual’s risk of developing a chronic indication. Genetic Technologies offers predictive testing as well as assessment tools for cancers and other diseases to aid physicians in proactively managing patient health.

GTG is developing a product pipeline of first-in-class, clinically validated risk assessment tests. The diagnostic Company is working to enhance the health outcomes for people across the globe by offering risk assessment tools to develop personalised health management strategies to detect and treat chronic diseases.​

The Company continually strives to maintain its position as a global leader in the genomics industry by investing in its research capabilities and collaborations with experts from world-class organisations, including universities, research organisations, and progressive medical product distribution companies.

Genetic Technologies owns and operates a world-class Clinical Laboratory Improvement Amendments (CLIA) authorised laboratory in Melbourne, Australia. The Company has collaborative agreements with other laboratory operators worldwide for ensuring the availability of its world-class genetic tests in selected jurisdictions.

GTG’s lead products include GeneType for Breast Cancer and GeneType for Colorectal Cancer.

GeneType for Breast Cancer (non-hereditary breast cancer)

GeneType for Breast Cancer can determine the risk of a woman developing sporadic breast tumour over a period. Three key factors contributing to the risk of developing sporadic breast cancer include genetic markers, family history, and breast density.

GeneType for Breast Cancer combines all the risk factors to offer a more accurate assessment of the risk of developing breast cancer.

GeneType for Colorectal Cancer

GeneType test for Colorectal Cancer can determine the risk of developing colorectal tumour over a period. The test combines several factors, including the patient’s family history, age, and genetic markers, to provide a more precise assessment of the risk of developing colorectal cancer.

The Company is also developing risk assessment test for type 2 diabetes, cardiovascular indications, prostate cancer, melanoma, and COVID-19.

Corporate Information

company address 60-66 Hanover Street, FITZROY, VIC, AUSTRALIA, 3065

company phone(03) 8412 7000

company email[email protected]

company websitehttp://www.gtglabs.com

Dividends

Ex-Dividend Date Franking DPS (AUD) Dividend Yield
30/06/2021 -- 0.000 0.00%
30/06/2020 -- 0.000 0.00%
30/06/2019 -- 0.000 0.00%
30/06/2018 -- 0.000 0.00%
30/06/2017 -- 0.000 0.00%
30/06/2016 -- 0.000 0.00%
30/06/2015 -- 0.000 0.00%
30/06/2014 -- 0.000 0.00%
30/06/2013 -- 0.000 0.00%
30/06/2012 -- 0.000 0.00%

Event Calendar

Event Type Event Date Event Year
Report (Annual) 2022-08-30 2022
Report (Prelim) 2022-08-30 2022
Report (Interim) 2022-02-25 2022

Financials

Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Trading Revenue 120,554 9,864 25,444 189,254 518,506
Other Revenue 1.502 M 1.314 M 667,792 1.082 M 305,347
Total Revenue 1.623 M 1.324 M 693,236 1.271 M 823,853
Interest Income 62,394 22,507 0 15,218 38,765
Interest Expenses -14,049 -14,823 -20,031 -28,843 -31,995
Expenses -8.483 M -7.365 M -6.86 M -5.89 M -8.318 M
EBITDA -6.86 M -6.041 M -6.167 M -4.619 M -7.494 M
Depreciation and Amortization -265,748 -65,148 -182,811 -303,749 -371,611
Depreciation -265,748 -65,148 -182,811 -303,749 -307,828
Amortisation 0 0 0 0 -63,783
EBIT -7.126 M -6.107 M -6.35 M -4.923 M -7.866 M
Pre Tax Profit -7.078 M -6.099 M -6.37 M -4.937 M -7.859 M
Tax Expense 0 0 0 0 0
Net Profit After Tax -7.078 M -6.099 M -6.37 M -4.937 M -7.859 M
Minority Interest 0 0 0 0 0
Preference Dividend 0 0 0 0 0
Net Abnormal Items 0 0 -500,000 -527,049 -544,694
Reported Net Profit After Abnormal Items -7.078 M -6.099 M -6.87 M -5.464 M -8.404 M
Ending Shares 9.017 B 7.514 B 3.148 B 2.609 B 2.609 B
Weighted Average Shares 8.544 B 4.155 B 2.824 B 2.609 B 2.273 B
EPS After Abnormal Items (cents) -0.08 -0.15 -0.24 -0.21 -0.37
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Total Current Assets 22.236 M 15.193 M 2.751 M 5.991 M 11.632 M
Total Non Current Assets 735,574 440,230 69,333 175,284 476,648
Total Assets 22.972 M 15.633 M 2.821 M 6.166 M 12.108 M
Total Current Liabilities 1.405 M 1.398 M 1.493 M 1.451 M 1.465 M
Total Non Current Liabilities 33,272 1.22 M 809 3,390 63,960
Total Liabilities 1.439 M 2.618 M 1.494 M 1.454 M 1.529 M
Net Assets 21.533 M 13.015 M 1.327 M 4.712 M 10.579 M
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Net Operating Cash -6.296 M -5.712 M -6.521 M -5.621 M -6.814 M
Net Invested Cash -748,706 64,787 -76,860 -2,385 -182,149
Net Financing Cash Flows 13.69 M 18.36 M 3.126 M -9,963 7.11 M
Beginning Cash 14.214 M 2.132 M 5.487 M 10.988 M 11.18 M
End Cash Position 20.902 M 14.214 M 2.132 M 5.487 M 10.988 M
Exchange Rate Adjustments 42,761 -630,616 116,186 132,443 -305,693
Other Cash Adjustments 0 0 0 0 0
Ending Cash 20.902 M 14.214 M 2.132 M 5.487 M 10.988 M

© Morningstar, Inc. 2021. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the market indices, commodities and regulatory news headlines, and other data or content contained herein to be accurate, complete, or timely, and nor shall they have any liability for its use or distribution. The data contained herein: (1) is proprietary to Morningstar and/or its affiliates (collectively, “Morningstar”) and/or their content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Our publications, ratings and products should be viewed as an additional investment resource, and not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your financial situation, contact a professional financial adviser. Some material is copyrighted and published under licence from ASX Operations Pty. Ltd. ACN 004523782.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK